{"id":7749,"date":"2026-04-28T16:47:46","date_gmt":"2026-04-28T13:47:46","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=7749"},"modified":"2026-04-28T16:47:47","modified_gmt":"2026-04-28T13:47:47","slug":"sgt-003-eu-orphan-drug-duchenne","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/sgt-003-eu-orphan-drug-duchenne\/","title":{"rendered":"Avrupa Komisyonu, Duchenne Kas Distrofisi \u0130\u00e7in SGT-003&#039;e Yetim \u0130la\u00e7 Stat\u00fcs\u00fc Verdi"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Avrupa Komisyonu, Solid Biosciences taraf\u0131ndan geli\u015ftirilen ve Duchenne kas distrofisi (DMD) tedavisi i\u00e7in umut vadeden bir gen terapisi olan SGT-003&#039;e Yetim \u0130la\u00e7 Stat\u00fcs\u00fc verdi.<\/strong>. Bu d\u00f6n\u00fcm noktas\u0131, kar\u015f\u0131lanmam\u0131\u015f y\u00fcksek t\u0131bbi ihtiya\u00e7lar\u0131 olan nadir hastal\u0131klar\u0131 hedefleyen yenilik\u00e7i tedavilere y\u00f6nelik artan d\u00fczenleyici deste\u011fi vurgulamaktad\u0131r.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#what-is-sgt-003\">SGT-003 nedir?<\/a><\/li><li><a href=\"#regulatory-milestone-orphan-drug-designation\">D\u00fczenleyici D\u00f6n\u00fcm Noktas\u0131: Yetim \u0130la\u00e7 Stat\u00fcs\u00fc<\/a><\/li><li><a href=\"#global-regulatory-momentum\">K\u00fcresel D\u00fczenleyici \u0130vme<\/a><\/li><li><a href=\"#ongoing-clinical-trials\">Devam Eden Klinik Ara\u015ft\u0131rmalar<\/a><\/li><li><a href=\"#why-this-matters-for-duchenne-patients\">SGT-003 Gen Terapisinin Yetim \u0130la\u00e7 Stat\u00fcs\u00fc Almas\u0131n\u0131n \u00d6nemi Nedir?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-sgt-003\"><strong>SGT-003 nedir?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SGT-003, Duchenne kas distrofisinin (DMD) alt\u0131nda yatan genetik nedeni hedef alan deneysel bir gen terapisidir. Terapi, distrofin geninin i\u015flevsel bir versiyonunu sunarak kas fonksiyonunu iyile\u015ftirmeyi ve hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatmay\u0131 ama\u00e7lamaktad\u0131r. Daha fazla bilgi edinin: <a href=\"https:\/\/dmdwarrior.com\/tr\/faq-solid-biosciences-sgt-003-gene-therapy\/\" target=\"_blank\" rel=\"noreferrer noopener\">SGT-003 Gen Terapisi Hakk\u0131nda S\u0131k\u00e7a Sorulan Sorular<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"regulatory-milestone-orphan-drug-designation\"><strong>D\u00fczenleyici D\u00f6n\u00fcm Noktas\u0131: Yetim \u0130la\u00e7 Stat\u00fcs\u00fc<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Avrupa Komisyonu taraf\u0131ndan verilen Yetim \u0130la\u00e7 Stat\u00fcs\u00fc, Avrupa \u0130la\u00e7 Ajans\u0131 Yetim T\u0131bbi \u00dcr\u00fcnler Komitesi&#039;nin olumlu g\u00f6r\u00fc\u015f\u00fcn\u00fcn ard\u0131ndan verilmi\u015ftir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu unvan, \u00e7e\u015fitli \u00f6nemli avantajlar sa\u011flamaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>AB&#039;de pazar m\u00fcnhas\u0131rl\u0131\u011f\u0131<\/li>\n\n\n\n<li>Azalt\u0131lm\u0131\u015f d\u00fczenleme \u00fccretleri<\/li>\n\n\n\n<li>Protokol deste\u011fine eri\u015fim<\/li>\n\n\n\n<li>Geli\u015ftirilmi\u015f geli\u015fim deste\u011fi<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Jessie Hanrahan&#039;a g\u00f6re, bu tan\u0131nma, SGT-003&#039;\u00fcn d\u00fcnya genelinde Duchenne hastalar\u0131n\u0131n kar\u015f\u0131lanmam\u0131\u015f kritik ihtiya\u00e7lar\u0131n\u0131 giderme potansiyelini g\u00fc\u00e7lendiriyor.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"global-regulatory-momentum\"><strong>K\u00fcresel D\u00fczenleyici \u0130vme<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SGT-003, \u00f6nemli pazarlarda \u00e7ok say\u0131da d\u00fczenleyici onay alarak g\u00fc\u00e7l\u00fc uluslararas\u0131 uyumlulu\u011funu g\u00f6stermi\u015ftir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>ABD G\u0131da ve \u0130la\u00e7 \u0130daresi&#039;nden:\n<ul class=\"wp-block-list\">\n<li>H\u0131zl\u0131 Yol atamas\u0131<\/li>\n\n\n\n<li>Yetim \u0130la\u00e7 stat\u00fcs\u00fc<\/li>\n\n\n\n<li>Nadir Pediatrik Hastal\u0131k tan\u0131m\u0131<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>Birle\u015fik Krall\u0131k d\u00fczenleyici \u00e7er\u00e7evesinden:\n<ul class=\"wp-block-list\">\n<li>\u0130novasyon Lisans\u0131 ve Eri\u015fim Yolu Kapsam\u0131nda \u0130novasyon Pasaportu<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu atamalar, geli\u015ftirme s\u00fcre\u00e7lerini h\u0131zland\u0131r\u0131r ve d\u00fczenleyici kurumlarla daha yak\u0131n i\u015fbirli\u011fini kolayla\u015ft\u0131r\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"ongoing-clinical-trials\"><strong>Devam Eden Klinik Ara\u015ft\u0131rmalar<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SGT-003 \u015fu anda iki b\u00fcy\u00fck klinik \u00e7al\u0131\u015fmada de\u011ferlendirilmektedir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong><a href=\"https:\/\/dmdwarrior.com\/tr\/solid-biosciences-provides-update-on-inspire-duchenne-clinical-trial-progress-and-planned-regulatory-discussions\/\">INSPIRE DUCHENNE<\/a><\/strong><br>Faz 1\/2 \u00e7al\u0131\u015fmas\u0131, g\u00fcvenlik ve erken etkinlik de\u011ferlendirmesi<\/li>\n\n\n\n<li><strong><a href=\"https:\/\/dmdwarrior.com\/tr\/solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634\/\">IMPACT DUCHENNE<\/a><\/strong><br>Faz 3 randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc \u00e7al\u0131\u015fma<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu denemeler, birden fazla b\u00f6lgede d\u00fczenleyici onay s\u00fcre\u00e7lerini desteklemek amac\u0131yla tasarlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-this-matters-for-duchenne-patients\"><strong>SGT-003 Gen Terapisinin Yetim \u0130la\u00e7 Stat\u00fcs\u00fc Almas\u0131n\u0131n \u00d6nemi Nedir?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi, s\u0131n\u0131rl\u0131 tedavi se\u00e7eneklerine sahip, \u015fiddetli ve ilerleyici bir genetik hastal\u0131kt\u0131r. SGT-003 gibi gen terapilerindeki ilerleme, semptom y\u00f6netiminden hastal\u0131\u011f\u0131 de\u011fi\u015ftiren m\u00fcdahalelere do\u011fru potansiyel bir paradigma de\u011fi\u015fimini temsil etmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu Sayfay\u0131 Takip Edin<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne i\u00e7in T\u00fcm Klinik Ara\u015ft\u0131rmalar<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The European Commission has granted Orphan Drug Designation to SGT-003, a promising gene therapy developed by Solid Biosciences, for the treatment of Duchenne muscular dystrophy (DMD). This milestone highlights growing regulatory support for innovative therapies targeting rare diseases with high unmet medical needs. What Is SGT-003? SGT-003 is an investigational gene therapy designed to address [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7750,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[680,61,195,681,110,170,109],"class_list":["post-7749","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-dmd-orphan-drugs","tag-gene-therapy","tag-orphan-drug","tag-orphan-drug-designation","tag-sgt-003","tag-sgt-003-gene-therapy","tag-solid-biosciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/7749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=7749"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/7749\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/7750"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=7749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=7749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=7749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}